Targeting signaling pathways with andrographolide in cancer therapy (Review)

• Published in: Molecular and Clinical Oncology
• Main Author: Shaharudin N.S.; Singh G.K.S.; Kek T.L.; Sultan S.
• Format: Review
• Language: English
• Published: Spandidos Publications 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205233316&doi=10.3892%2fmco.2024.2779&partnerID=40&md5=458ce94d41cd17306a66a93fab5dd50c

Terpenoids are a large group of naturally occur-ring organic compounds with a wide range of components. A phytoconstituent in this group, andrographolide, which is derived from a plant called Andrographis paniculateoffers a number of advantages, including anti-inflammatoryanticancer, anti-angiogenesis and antioxidant effects. The present review elucidates the capacity of andrographolide to inhibit signaling pathways, namely the nuclear factor-κB (NF-κB), hypoxia-inducible factor 1 (HIF-1), the Janus kinase (JAK)/signal transducer and activator of transcription (STAT), phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), Wnt/β-catenin and mitogen-activated protein kinase (MAPK) pathways, which are involved in cellular processes and responses such as the inflammatory response, apoptosis and angiogenesis. Inhibiting pathways enables andrographolide to exhibit its anticancer effects against breast, colorectal and lung cancer. The present review focuses on the anticancer effects of andrographolide, specifically in breast, colorectal and lung cancer through the NF-κB, HIF-1 and JAK/STAT signaling pathways. Therefore, the Google Scholar, PubMed and ScienceDirect databases were used to search for references to these prevalent types of cancer and the anticancer mechanisms of andrographolide associated with them. The following key words were used: Andrographolide, anticancer, JAK/STAT, HIF-1, NF-κB, PI3K/AKT/mTOR, Wnt/β-catenin and MAPK pathways, and the literature was limited to studies published between 2010 to 2023. The present review article provides details about the different involvements of signaling pathways in the anticancer mechanisms of andrographolide. © 2024 Shaharudin et al.